

## **IN THE SPECIFICATION**

- (1) Delete the first paragraph after the title on page 1 and substitute the following paragraph:

This application is a division of co-pending application U.S. Serial No. 09/789,720 filed February 22, 2001, which is a division of U.S. Serial No. 09/150,622 filed September 10, 1998, now issued as U.S. Patent 6,268,411, Serial No. 09/150,622, which claims the benefit of co-pending applications U.S. Serial No. 60/058,573 filed September 11, 1997 and U.S. Serial No. 60/082,538 filed April 21, 1998. ~~Each of these applications is,~~ which are incorporated by reference ~~in its entirety~~ herein.

- (2) Delete the paragraph on page 6, lines 2-7, and substitute it with:

**Figure 1.** Figure 1A, schematic of chimeric MHC/Ig molecules formed in a conformationally intact fashion at the ends of the immunoglobulin heavy chains. Figure 1B, schematic of the pA2/Ig plasmid containing the regions encoding the extracellular domains (~~SEQ ID NO:6; SEQ ID NO:7~~) ( $\alpha 1$ - $\alpha 3$ ) of the HLA-A2 class I MHC molecule genetically linked to the variable region of an IgG1 heavy chain gene. Expanded portion of Figure 1B shows the 5' *Mlu*I site (ACGCG; "LINK") and 3' *Not*I site (GCGGCCGC; "LINK") which link  $\alpha 1$ - $\alpha 3$  to the variable region of the IgG1 heavy chain as described in Example 9. Nucleotide sequence in Figure 1B is SEQ ID NO:6; amino acid sequence in Figure 1B is SEQ ID NO:7.